Key result
Patients with CRT devices were significantly more likely to receive target doses of β-blockers than those without devices (CRT-D 20.4% vs no device 15.3%), though overall target dosing was low.
Why the study?
Does device therapy improve the delivery of target doses of evidence-based medical therapy in outpatients with systolic heart failure?
Observational (n=15,381)
Yes
Does device therapy improve the delivery of target doses of evidence-based medical therapy in outpatients with systolic heart failure?
In outpatients with HFrEF, those with device therapy (CRT) are more likely to receive target doses of beta-blockers, though overall achievement of target doses for guideline-directed medical therapy remains low across all patients.
No takes yet. Share an insight, caveat, or question.
CRT was associated with higher β-blocker target dosing in HFrEF outpatients; hypothesis-generating for device effects on GDMT optimization.
Heywood et al. (2010) conducted an observational in systolic heart failure (n=15,381). Device therapy (ICD, CRT-D, CRT-P) vs. No device therapy was evaluated on Treatment at or above target doses for ACE inhibitors/ARBs, β-blockers, and aldosterone antagonists. Patients with CRT devices were significantly more likely to receive target doses of β-blockers than those without devices (CRT-D 20.4% vs no device 15.3%), though overall target dosing was low.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: